Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing. That…
Blog
FDA’s Moderna decision demonstrates how science and government are incompatible
Last week, the FDA announced that it would not be considering Moderna’s application for a new flu vaccine because the control group Moderna used…
Blog
Congress gets into the PBM business
In the recently passed appropriations bill, Congress enacted several Pharmacy Benefit Manager (PBM) reforms it has been contemplating for years. On the surface, these…
Blog
HSAs: A silver bullet for the silver loading conundrum
After the longest government shutdown in American history — ostensibly caused by the expiration of the expanded Obamacare subsidies — Republicans have debated health care…
Blog
Obamacare’s subsidy cliff: How many enrollees are actually affected?
Democrats in Congress have put Obamacare front and center in their opposition to the Republicans’ temporary budget. One provision of the American Rescue Plan…
Blog
The TrumpRx medicine will prove worse than the disease
On September 30, President Trump, standing alongside the CEO of Pfizer, announced a multifaceted deal wherein Pfizer would inoculate itself from new regulations and…